trending Market Intelligence /marketintelligence/en/news-insights/trending/ZNeoyrs_HSnd8oaJwcHIew2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioMarin's hemophilia gene therapy granted EMA accelerated assessment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BioMarin's hemophilia gene therapy granted EMA accelerated assessment

BioMarin Pharmaceutical Inc.'s experimental hemophilia gene therapy has been granted accelerated assessment by the European Medicines Agency, ahead of the rare disease drug developer's planned application for approval.

During its Oct. 23 third-quarter earnings call, BioMarin executives said the therapy, called Valrox, will be submitted for European and U.S. approval in the fourth quarter.

If approved, Valrox could be launched in the second half of 2020, BioMarin said in its earnings release.

SNL Image

San Rafael, Calif.-based BioMarin's shares were up about 4.3% to $72.00 in after-hours trading Oct. 23.

Valrox is intended to replace hemophilia A patients' missing factor VIII levels and thus reduce bleeding. According to a three-year study, patients treated with Valrox saw a 96% reduction in mean annualized bleed rate. Factor VIII levels in the study participants appeared to fall over three years, though analysts noted that the levels may have stabilized and reached a plateau at year three.

BioMarin said Valrox's effects should be sustained over eight or more years.

Currently, the standard of care for hemophilia A is factor VIII infusions, typically administered two to three times a week.

Accelerated assessment, granted by the EMA to medicines of major public health interest, speeds up the time it takes for the Committee for Medicinal Products for Human Use to review an application.